Current Treatments

The first approved antimetabolites, 5-FU and MTX, have been in clinical use since for over 40 years. Both 5-FU and MTX were initially developed to treat carcinomas, but MTX and later other nucleoside analogs were found to be useful agents in hematopoietic therapy. However, in recent years, more antimetabolites have been developed to be effective in the treatment of solid tumors (Tables 3 and 4). Five antimetabolites have been approved for clinical use since 1996: gemcitabine, capecitabine, pemetrexed, azacitidine, and clofarabine. New methods for delivery of antimetabolites have

0 0

Post a comment